ACE Management manages seven investment funds representing approximately € 300 million in capital on behalf of purchasers of industrial and financial leaders such as:
- EADS, Airbus,
- Thales, Safran, DCNS, CEA,
- Caisse des Dépôts, France Investissement, Fonds de Solidarite des Travailleurs du Quebec (FSTQ), Société Générale, Crédit Agricole, CIC or AXA.
ACE Management covers a wide spectrum of activities:
- Venture capital
- Development capital
- Buyout Leverage (LBO) financing
- Industrial spin-offs of financing building operations (LBU)
With a strong entrepreneurial culture and industry background, ACE Management invests in companies with high technology content, growing and able to play a role in structuring their business segment. The management team since the creation of Financière de Brienne in 1993, has invested in nearly 110 companies.
Bio Modeling Systems
Bio-Modeling Systems is a S.A.S Company, incorporated in 2004 in Paris – France, privately owned by its founders, Manuel Géa and François Iris and member of BIO (Biotechnology Industry Organization USA).
BMSystems is involved in predictive integrative biology. As a research-based biotech company, BMSystems creates CADI™ (Computer Assisted Deductive Integration) models with immediate applications generating highly attractive businesses, through contractual/collaborative research programs.
Auriga Partners is an independent Innovation Capital company, based in Paris. It invests equity in the Digital and Life Sciences fields, in innovative projects with high potential, from the initial development stage up to the international commercial expansion phase. Now in its fourth generation of funds, AURIGA Partners currently manages a total of more than €350 million, supporting and advising its portfolio companies notably regarding their international expansion and the structure of their management teams.
The team has backed several dozen projects which have achieved success in the form of M&A or IPOs, in particular: EVE (Synopsys), Neolane (Adobe), Novagali (Santen), Oxand (Latour), Amoeba (EuroNext), Cellnovo (EuroNext), Ekinops (EuroNext), Erytech (EuroNext), Genocea (Nasdaq), Implanet (EuroNext), Miliboo (AlterNext), Median (AlterNext), Supersonic Imagine (EuroNext), TxCell (EuroNext) and Wallix (AlterNext).